Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 126

1.

Successful multifold dose escalation of anti-GD2 monoclonal antibody 3F8 in patients with neuroblastoma: a phase I study.

Kushner BH, Kramer K, Modak S, Cheung NK.

J Clin Oncol. 2011 Mar 20;29(9):1168-74. doi: 10.1200/JCO.2010.28.3317. Epub 2011 Feb 22.

2.
3.

Key role for myeloid cells: phase II results of anti-G(D2) antibody 3F8 plus granulocyte-macrophage colony-stimulating factor for chemoresistant osteomedullary neuroblastoma.

Cheung NK, Cheung IY, Kramer K, Modak S, Kuk D, Pandit-Taskar N, Chamberlain E, Ostrovnaya I, Kushner BH.

Int J Cancer. 2014 Nov 1;135(9):2199-205. doi: 10.1002/ijc.28851. Epub 2014 Apr 3.

4.

Anti-G(D2) antibody treatment of minimal residual stage 4 neuroblastoma diagnosed at more than 1 year of age.

Cheung NK, Kushner BH, Cheung IY, Kramer K, Canete A, Gerald W, Bonilla MA, Finn R, Yeh SJ, Larson SM.

J Clin Oncol. 1998 Sep;16(9):3053-60.

PMID:
9738575
5.
7.
8.

Lack of survival advantage with autologous stem-cell transplantation in high-risk neuroblastoma consolidated by anti-GD2 immunotherapy and isotretinoin.

Kushner BH, Ostrovnaya I, Cheung IY, Kuk D, Modak S, Kramer K, Roberts SS, Basu EM, Yataghene K, Cheung NK.

Oncotarget. 2016 Jan 26;7(4):4155-66. doi: 10.18632/oncotarget.6393.

9.

Posterior reversible encephalopathy syndrome in neuroblastoma patients receiving anti-GD2 3F8 monoclonal antibody.

Kushner BH, Modak S, Basu EM, Roberts SS, Kramer K, Cheung NK.

Cancer. 2013 Aug 1;119(15):2789-95. doi: 10.1002/cncr.28137. Epub 2013 Apr 30.

10.

Disialoganglioside GD2 anti-idiotypic monoclonal antibodies.

Cheung NK, Canete A, Cheung IY, Ye JN, Liu C.

Int J Cancer. 1993 May 28;54(3):499-505.

PMID:
8509225
11.

3F8 monoclonal antibody treatment of patients with stage 4 neuroblastoma: a phase II study.

Cheung NK, Kushner BH, Yeh SD, Larson SM.

Int J Oncol. 1998 Jun;12(6):1299-306.

PMID:
9592190
12.

Disialoganglioside G(D2) loss following monoclonal antibody therapy is rare in neuroblastoma.

Kramer K, Gerald WL, Kushner BH, Larson SM, Hameed M, Cheung NK.

Clin Cancer Res. 1998 Sep;4(9):2135-9.

13.

Ganglioside GD2 specific monoclonal antibody 3F8: a phase I study in patients with neuroblastoma and malignant melanoma.

Cheung NK, Lazarus H, Miraldi FD, Abramowsky CR, Kallick S, Saarinen UM, Spitzer T, Strandjord SE, Coccia PF, Berger NA.

J Clin Oncol. 1987 Sep;5(9):1430-40.

PMID:
3625258
14.

Murine anti-GD2 monoclonal antibody 3F8 combined with granulocyte-macrophage colony-stimulating factor and 13-cis-retinoic acid in high-risk patients with stage 4 neuroblastoma in first remission.

Cheung NK, Cheung IY, Kushner BH, Ostrovnaya I, Chamberlain E, Kramer K, Modak S.

J Clin Oncol. 2012 Sep 10;30(26):3264-70. doi: 10.1200/JCO.2011.41.3807. Epub 2012 Aug 6.

15.

FCGR2A polymorphism is correlated with clinical outcome after immunotherapy of neuroblastoma with anti-GD2 antibody and granulocyte macrophage colony-stimulating factor.

Cheung NK, Sowers R, Vickers AJ, Cheung IY, Kushner BH, Gorlick R.

J Clin Oncol. 2006 Jun 20;24(18):2885-90. Epub 2006 May 8. Erratum in: J Clin Oncol. 2006 Aug 10;24(23):3814.

PMID:
16682723
16.

Disaloganglioside GD2 loss following monoclonal antibody therapy is rare in neuroblastoma.

Kramer K, Gerald WL, Kushner BH, Larson SM, Hameed M, Cheung NK.

Med Pediatr Oncol. 2001 Jan;36(1):194-6.

PMID:
11464881
17.

Antibody response to murine anti-GD2 monoclonal antibodies: correlation with patient survival.

Cheung NK, Cheung IY, Canete A, Yeh SJ, Kushner B, Bonilla MA, Heller G, Larson SM.

Cancer Res. 1994 Apr 15;54(8):2228-33.

18.

Supplemental Content

Support Center